throbber
United States Patent [19]
`Juraszyk et al.
`
`US005614535A
`[ii] Patent Number:
`[45] Date of Patent:
`
`5,614,535
`Mar. 25, 1997
`
`[54] ADHESION RECEPTOR ANTAGONISTS
`
`[75]
`
`Inventors: Horst Juraszyk; Joachim Gante;
`Hanns Wurziger; Sabine
`Bernotat-Danielowski; Guido Melzer,
`all of Darmstadt, Germany
`
`0462960 12/1991 European Pat. Off. .
`0459256 12/1991 European Pat. Off. .
`0645376
`3/1995 European Pat. Off. .
`4405633 11/1994 Germany .
`
`OTHER PUBLICATIONS
`
`[73] Assignee: Merck Patent Gesellschaft Mit
`Beschrankter Haftung, Darmstadt,
`Germany
`
`[21] Appl. No.: 516,937
`Aug. 18, 1995
`[22] Filed:
`Foreign Application Priority Data
`
`[30]
`
`Aug. 19, 1994
`[51] Int. CI.6
`
`44 29 461.1
`[DE] Germany
`A61K 31/445; A61K 31/42;
`C07D 263/24; C07D 413/12
`514/326; 514/212;
`[52] U.S. CI.
`514/255;
`514/364; 514/374; 540/603; 544/369; 546/208;
`548/134; 548/135; 548/230
`[58] Field of Search
`540/603; 544/369;
`546/208; 548/134, 135, 230; 514/212, 255,
`326, 364, 374
`
`[56]
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`3/1948 Homeyer et al
`2,437,388
`9/1989 Schnettler et al
`4,866,182
`5,356,918 10/1994 Ishihara et al
`
`548/230
`548/230
`514/376
`
`FOREIGN PATENT DOCUMENTS
`
`0381033
`
`8/1990 European Pat. Off. .
`
`chro­
`liquid
`high performance
`
`Vajta et al. "Reversed-phase
`matographic separation of 14C-labeled toloxatone and tis
`metabolites" CA 102:5518 1984.
`Bom, Nature, 4832:927-929
`(1962).
`Smith et al., J. Biol. Chem., 265:12267-12271 (1990).
`
`Primary Examiner—Ceila Chang
`Attorney, Agent, or Firm—Millen, White, Zelano, & Brani-
`gan, RC.
`
`[57]
`
`ABSTRACT
`
`Compounds of the formula I
`
`o
`
`X
`
`I
`
`v.'
`y
`
`R1'
`
`o
`in which R1 and X have the meanings herein defined, their
`salts
`and/or
`physiologically unobjectionable
`the binding of fibrinogen to the corresponding receptor and
`can be employed for
`the
`treatment of
`thromboses,
`osteoporosis,
`tumoral
`diseases,
`apoplexy,
`cardiac
`inflammations, arteriosclerosis and osteolytic disorders.
`
`solvates
`
`infarction,
`
`20 Claims, No Drawings
`
`MYLAN - EXHIBIT 1020
`
`

`
`1
`ADHESION RECEPTOR ANTAGONISTS
`
`SUMMARY OF THE INVENTION
`
`5,614,535
`
`2
`
`n is 1, 2, 3 or 4,
`p is 0, 1 or 2,
`q is 0 or 1,
`r is 1 or 2,
`A is alkyl of 1 to 6 carbon atoms,
`—alk— is alkylene of 1 to 6 carbon atoms,
`Ar is phenyl or benzyl, and
`Ph is phenylene,
`and their physiologically unobjectionable salts and/or
`solvates.
`Compounds having a similar activity profile are known
`from EP-A1-0 381 033.
`An object of the invention is to provide novel compounds
`15 having valuable properties, in particular those compounds
`which can be used for preparing medicaments.
`Upon further study of the specification and appended
`claims, further objects and advantages of this invention will
`become apparent to those skilled in the art.
`These objects are achieved by the invention. It has been
`found that the compounds of the formula I and their solvates
`and salts possess valuable pharmacological properties while
`being well tolerated. In particular, they inhibit the binding of
`fibrinogen, fibronectin
`and the yon Willebrand factor to the
`fibrinogen receptor of blood platelets (glycoprotein Eb/IIIa),
`25 as well as the binding of these proteins and of further
`adhesive proteins, such as vitronectin, collagen and laminin,
`to the corresponding receptors on the surface of various cell
`types. The compounds consequently influence cell-cell and
`cell-matrix interactions. They prevent the development of
`30 blood-platelet thrombi in particular, and can therefore be
`used for the treatment of thromboses, apoplexy, cardiac
`infarction, inflammations and arteriosclerosis. In addition,
`the compounds have an effect on tumor cells, by preventing
`them from forming metastases. Consequently, they can also
`35 be used as antitumor agents.
`There is evidence that tumor cells spreading from a solid
`tumor into the vasculature are carried by microthrombi, i.e.,
`microaggregates of tumor cells and platelets. As a result, the
`tumor cells in the microthrombi are protected from being
`40 detected by cells of the immune system. The second step of
`attachment to the vessel wall seems to be facilitated by
`microthrombi as well. Since the formation of thrombi is
`mediated by fibrinogen binding to the fibrinogen
`receptor
`(glycoprotein Ilb/IIIa) on activated platelets, fibrinogen-
`45 binding inhibitors are expected to be effective as antimeta-
`statics.
`inhibitors are ligands with
`Also, since fibrinogen-binding
`fibrinogen receptor on platelets, they can be used as diag­
`nostic tools for detection and localization of thrombi in the
`50 vascular in vivo. Thus, for example, in accordance with
`known procedures, the fibrinogen-binding
`inhibitors can be
`labeled with a signal generating or detectable moiety
`whereby, once the labeled fibrinogen-binding
`inhibitor is
`bound to a fibrinogen receptor on platelets, it is possible to
`detect and locate thrombi.
`Fibrinogen-binding inhibitors are also very effective as
`research tools for studying the metabolism of platelets in the
`different activation states or intracellular signalling mecha­
`nisms of the fibrinogen receptor. For example, as described
`60 above, fibrinogen-binding
`inhibitor can be labeled with a
`signal generating or detectable moiety. The fibrinogen-
`binding inhibitor-signal generating/detectable moiety con­
`jugate can then be employed in vitro as a research tool. By
`binding the conjugate to fibrinogen receptors, it is possible
`|_0 rnonitor and study the metabolism of platelets, as well as
`the activation states and signalling mechanisms of the
`fibrinogen receptors.
`
`The invention relates to oxazolidinonecarboxylic acid 5
`derivatives of the formula I
`
`O
`
`x
`
`I
`
`R1'
`
`o
`
`!
`0
`
`10
`
`wherein
`,
`R1
`is N02, NR6R7, CN, CONR6R7, CSNR6R7
`C(=NH)SA,
`C(=NH)OA,
`C(=NH)SAr.
`7'
`C(=)NR6R7,
`C(=NH)NHOH,
`CH2NR6R ,
`NHC(=NH)NR6R7,
`CH2NHC(=NH)NR6R7,
`CH2NHCO—alk—NR6R7,
`CH2NHCO—Ph—E,
`CH2NHCONH— 20
`CH2NHCO—Ph—CH2NR6R7,
`Ph—E or D,
`X is OH, OA, AS, AS—AS',
`
`Y \
`
`N—R3 or — N—(CH2)» ,
`
`R4
`
`—N
`
`D is
`
`\
`
`N Y
`
`R2
`
`E is —CN, —C(=NH)OA, —CSNH2, —C(=NH)SA or
`—C(=NH)NH2,
`Y is CH2, CHOR5 or C=0,
`R2 is H, A, Ar, OH, OA, CF3, CCI3, NR6R7, —alk—
`NR6R7, —alk(CH2Ar)NR6R7, or
`
`O
`\\
`
`-CH2-N
`
`0
`
`R3 is — (CH2)m—COOR5,
`R4 is — (CH2)p—COOR5 or — (CH2)9—O—(CH2) —
`COOR5,
`AS or AS' is in each case, independent of the other, an
`amino-acid residue selected from Ala, (5-Ala, Arg, Asn,
`Asp, Gin, Glu, Gly, Leu, Lys, Om, Phe, Pro, Sar, Ser,
`Thr, Tyr, Tyr (OMe), Val, C-allyl-Gly, C-propargyl-Gly,
`N-benzyl-Gly, N-phenethyl-Gly, N-benzyl-p-Ala,
`N-methyl-P-Ala and N-phenethyl-P-Ala, it being pos­
`sible for free amino or carboxyl groups also to be
`provided with conventional protective groups which
`are known per se.
`R5, R6 and R7 are each, independent of one another, H or 55
`A,
`m is 1, 2 or 3,
`
`

`
`5,614,535
`
`3
`Furthermore, the compounds are suitable for the prophy­
`laxis and treatment of osteolytic disorders, especially
`osteoporosis and restenosis following angioplasty. In addi­
`tion, they have antiangiogenetic properties.
`Moreover, the compounds display an antimicrobial action s
`and can be employed in treatments and interventions in
`which it is necessary to prevent microbial infection. Anti­
`microbial activity of the compounds can be demonstrated by
`the procedure described by P. Valentin-Weigan et al., Infec­
`tion and Immunity, 2851-2855 (1988).
`The properties of the compounds can be demonstrated by
`methods which are described in EP-A1-0 462 960. The
`inhibition of the binding of fibrinogen
`to the fibrinogen
`receptor can be demonstrated by the method indicated in
`EP-A1-0 381 033. The inhibitory effect on blood-platelet
`aggregation can be demonstrated in vitro by the method of 15
`Bora (Nature, 4832:927-929 (1962)). The inhibition of the
`interactions of (^-integrin receptors with suitable ligands
`can be demonstrated by the method of J. W. Smith et al., J.
`Biol. Chem., 265:12267-12271 (1990).
`The invention relates to compounds of the indicated 20
`formula I, to their salts and solvates, and to a process for the
`preparation of these compounds, characterized in that
`(a) a compound of the formula I is liberated from one of
`its functional derivatives by treatment with a solvolyzing or
`hydrogenolyzing agent, or in that
`(b) a compound of the formula II
`
`25
`
`R1.
`
`O
`11
`
`L
`
`v»
`y °
`
`0
`
`II
`
`in which
`R1 has the meaning given and
`L is CI, Br, OH or a reactive esterified OH group or a
`leaving group which is readily capable of undergoing
`nucleophilic substitution,
`is reacted with a compound of the formula III
`
`H—X'
`
`HI,
`
`in which
`X' is AS, AS—AS',
`r Y
`\
`\
`/
`
`—N
`
`R4
`
`N—R3 or —N—(CHiJn .
`
`30
`
`35
`
`40
`
`45
`
`50
`
`where Y, R3, R4 and n have the meanings given, or in
`that
`c) a radical X is converted into a different radical X by 55
`hydrolyzing an ester of the formula I or esterifying a
`carboxylic acid of the formula I, or in that
`d) a radical R1 is converted into a different radical R1 by
`catalytically hydrogenating a NO2 and/or CN group, or
`converting a nitrile group by reaction with ammonia 60
`into a C(=NH)—NH2 group, or
`converting a nitrile group into a thiocarbamoyl group.
`or
`converting a thiocarbamoyl group into an alkyl-
`sulfimido group, or
`converting a carbamoyl group into an alkylimido
`group, or
`
`65
`
`4
`convening a methylsulfimido group into an amidine
`group, or
`converting a nitrile group by reaction with NH2OH into
`a C(=NH)—NHOH group, or
`converting a NH2 group into a guanidinyl group, or
`converting a C(—NH)—NHOH group into an amidine
`group, or
`converting a CH2NH2 group into an alkanoylaminom-
`ethyl, CH2NHC(=NH)NR6R7, CH2NHCO—Ph—
`C(=NH)NH2, CH2NHCO—Ph—CH2NR6R7 or a
`CH2NHC0NH—Ph—E group, or
`converting a 1,2,4-oxadiazole or 1,2,4-oxadiazolinone
`group into an amidine group,
`e) or in that a compound of the formula IV
`
`NH-CH2-CHOH-COX,
`
`IV
`
`R1'
`in which
`R1 and X have the given meanings, is reacted with a
`reactive derivative of carbonic acid, and/or in that
`f) a compound of the formula V
`
`/ \
`
`v
`
`OH
`
`HO—N
`w
`H2N
`OH
`is reacted with 2 equivalents of a reactive carbonic acid
`derivative and then oxidized, or in that
`g) a compound of the formula I is converted by treatment
`with an acid or a base into one of its salts.
`The abbreviations given above and below for amino-acid
`residues are the residues of the following amino acids:
`
`Ala
`P-Ala
`Arg
`Asn
`Asp
`Asp(0 But)
`Gin
`Glu
`Gly
`Leu
`Lys
`Om
`Phe
`Pro
`Sar
`Ser
`Thr
`Tyr
`Tyr(OMc)
`Val
`
`alanine
`p-alaninc
`arginine
`asparaginc
`aspartic acid
`aspartic acid P-butyl eslcr
`glutaminc
`glutamic acid
`glycine
`leucine
`lysine
`ornithine
`phenylalanine
`proline
`sarcosine (N-mcthylglycine)
`serine
`threonine
`tyrosine
`2-ainino-3-p-mcthoxyphenylpropionic acid
`valine.
`
`Further abbreviations used below arc:
`
`BOC
`CBZ
`DCCI
`DMF
`EDCI
`
`Et
`Me
`OMe
`OEt
`TEA
`
`tert-butoxycarbonyl
`benzyloxycarbonyl
`dicyclohexylcarbodiimide
`dimethylform amide
`N-ethyl-N'-(3-dimethylaminopropyl)-
`carbodiimide hydrochloride
`ethyl
`methyl
`methyl ester
`ethyl ester
`trifluoroacetic acid
`
`Above and below, the radicals R1 and X have the mean­
`ings given for the formula I. Where a compound of the
`
`

`
`5,614,535
`
`10
`
`5
`6
`formula I possesses a chiral center, it may occur in a
`methods which are known per se, as described in the
`plurality of enantiomeric forms. All of these forms and
`literature (e.g., in the standard works such as Houben-Weyl,
`mixtures thereof, especially racemates, are included by the
`Methoden der organischen Chemie [Methods for Organic
`invention.
`Chemistry], Georg-Thieme-Verlag, Stuttgart; and also J.
`In the formula above and below, the group A has 1-6, 5 March, Adv. Org. Chem., 3rd Ed. (1985), J. Wiley & Sons),
`preferably 1, 2, 3 or 4, carbon atoms. Specifically, A is
`specifically under reaction conditions which are known and
`preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl,
`suitable for the stated reactions. In this context, use can also
`sec-butyl or tert-butyl, and also pentyl, 1-, 2- or 3-methyl-
`be made of variants which are known per se which are not
`butyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl,
`mentioned here in more detail.
`or 1-, 2- or 3-methylpentyl.
`^ desired, the starting compounds can also be formed in
`f w
`nrH
`n n-T TH
`OH
`Y
`•
`fu' such th/ they 316 no}
`1 from ^ re1action
`4-carb1oSxyPp?peeriadinyo, 4-carboxyalkylpiperidino, 4-carboxy3-
`alkoxypiperidino and the corresponding alkyl ester groups
`but> msteJad' ?? rf cted1
`^mediately to give the
`compounds of the formula I.
`of the radicals mentioned, 4-alkoxycarbonylpiperidino,
`4-carboxymethylpiperazino, 4-carboxyethylpiperazino or,
`compounds of the formula I can be obtained by
`particularly preferably, is an amino-acid residue or a dipep- 15
`liberating them from their functional derivatives by solvoly-
`tide residue which is attached to the carbonyl group via an
`s's> i11 particular hydrolysis, or by hydrogenolysis.
`amide bond. If X is an amino-acid residue or dipeptide
`Preferred starting compounds for the solvolysis or hydro-
`residue, the following are particularly preferred: Ala, p-Ala,
`genolysis are those which, while otherwise corresponding to
`the formula I, contain corresponding protected amino and/or
`Gly, Arg and P-Ala-Asp, Phe, N-phenethylglycine, N-phen-
`20 hydroxyl groups in place of one or more free amino and/or
`ethyl-P-alanine or Sar.
`The C-terminal amino-acid residue can in this case like­
`hydroxyl groups, preferably those which carry an amino-
`wise be attached to a conventional protective group. An
`protective group in place of a hydrogen atom which is linked
`esterification is particularly suitable.
`to a nitrogen atom, in particular those which carry, in place
`The group R1 is preferably —NH2, —C(=NH)—NH2,
`of an HN group, a group R'—N in which R' is an amino-
`—CH2—NH2, —CH2—NH—CO—alk—NH2, —CH2—
`25 protective group, and/or those which carry, instead of the
`NH—CO—Ph—C(=NH)—NH2, —CH2—NH—CO—
`hydrogen atom of a hydroxyl group, a hydroxy-protective
`alk—C(=NH)—NH2, —CH2—NH—CO—Ph—CH2—
`group, for example those which correspond to the formula I
`NH2, N02 or CN. In addition, R1 is also preferably
`but, instead of a —COOH group, carry a group —COOR"
`—C(=NH)—S—A, —CSNH2, —C(=NH)—NHOH or
`in which R" is a hydroxy-protective group.
`It is also possible for two or more—identical or differ­
`ent—protected amino and/or hydroxyl groups to be present
`in the molecule of the starting compound. If the protective
`groups present are different from one another, they can in
`many cases be eliminated selectively.
`The expression "amino-protective group" is well known
`and relates to groups which are suitable for protecting (for
`The radical Ar is unsubstituted benzyl or phenyl.
`blocking) an amino group from chemical reactions but
`The parameters m and n are preferably 1, but also, in
`which are readily removable once the desired chemical
`addition, preferably 2 or 3. The variable p is preferably 0 or
`reaction has been carried out at another site of the molecule.
`1, whereas q and r are preferably 1.
`40 Typical groups of this kind are, in particular, unsubstituted
`Among the compounds of the formula I, preference is
`or substituted acyl, aryl (e.g., 2,4-dinitrophenyl (DNP)),
`given to those in which at least one of the indicated radicals,
`aralkoxymethyl (e.g., benzyloxymethyl (BOM)) or aralkyl
`groups and/or parameters has one of the preferred meanings
`groups (e.g., benzyl, 4-nitrobenzyl or triphenylmethyl).
`given. Some groups of preferred compounds are those of the
`Since the amino-protective groups are removed after the
`formulae la to If, which correspond to the formula I except 45 desired reaction (or sequence of reactions), their nature and
`that
`size is otherwise not critical; however, preference is given to
`in la R1 is C(=NH)NH2 and X is OH or OA;
`those having 1-20, especially 1-8 carbon atoms. In connec­
`tion with the present process, the expression "acyl group"
`in lb R1 is C(=NH)NH2 and X is 4-carboxypiperidino,
`should be interpreted in the broadest sense. It embraces acyl
`4-carboxylalkylpiperidino or 4-carboxyalkoxypiperi-
`50 groups derived from aliphatic, araliphatic, aromatic or het­
`dino;
`erocyclic carboxylic acids or sulfonic acids and also, in
`in Ic R1 is C(=NH)NH2 and X is (5-Ala, Asp, Tyr,
`particular, alkoxycarbonyl, aryloxycarbonyl and, especially,
`Tyr(OMe), N-phcnethyl-fi-Ala or Phe, and the corre­
`aralkoxycarbonyl groups. Examples of such acyl groups are
`sponding esterified derivatives;
`alkanoyl such as acetyl, propionyl, butyryl; aralkanoyl such
`in Id R1 is C(=NH)NH2 and X is 4-alkoxycarbonylpip-
`55 as phenylacetyl; aroyl such as benzoyl or tolyl; aryloxyal-
`eridino, 4-alkoxycarbonylpiperazino, 4-alkoxycarbo-
`kanoyl such as phenoxyacetyl; alkoxycarbonyl such as
`nylalkylpiperidino, 4-alkoxycarbonylalkoxypiperazino
`methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxy-
`or 4-alkoxycarbonylalkoxypiperidino;
`carbonyl, isopropoxycarbonyl, tert-butoxycarbonyl (BOC)
`in le R1 is C(=NH)NH2 and X is 4-carboxypiperazino or
`and 2-iodoethoxycarbonyl; aralkyloxycarbonyl such as ben-
`4-carboxyalkylpiperazino;
`60 zyloxycarbonyl (CBZ), 4-methoxybenzyloxycarbonyl and
`9-fluorenylmethoxycarbonyl (FMOC). Preferred amino-
`in If R1 is C(=NH)NHOH and X is one of the radicals
`protective groups are BOC, DNP and BOM, and also CBZ,
`mentioned under la to le.
`benzyl and acetyl.
`Furthermore, the invention includes all those compounds
`The expression "hydroxy-protective group" is likewise
`which have a NH2 group within which this NH2 group is
`65 well known and relates to groups which are suitable for
`provided with a protective group which is known per se.
`protecting a hydroxyl group against chemical reactions, but
`The compounds of the formula I, and also the starting
`which are readily removable once the desired chemical
`compounds for their preparation, are otherwise prepared by
`
`R2
`
`N
`
`.
`
`30
`
`35
`
`

`
`5,614,535
`
`7
`8
`reaction has been carried out at another site of the molecule.
`with a compound of the formula III. In this case use is
`Typical groups of this kind are the abovementioned unsub-
`advantageously made of the methods which are known per
`stituted or substituted aryl, aralkyl or acyl groups, and also
`se of nucleophilic substitution and/or of the N-alkylation of
`alkyl groups. The nature and size of the hydroxy-protective
`amines or the reactions for amide formation.
`groups is not critical, since after the desired chemical 5
`The leaving group L in the formula II is preferably CI, Br
`reaction or sequence of reactions they are removed again;
`or OH, or a group which can be derived therefrom, for
`preference is given to groups having 1-20, especially 1-10,
`example the trifluoromethanesulfonyloxy, toluenesulfony-
`carbon atoms. Examples of hydroxy-protective groups
`loxy or methanesulfonyloxy group.
`include tert-butyl, benzyl, p-nitrobenzoyl, p-toluenesulfonyl
`The reaction is preferably carried out in the presence of an
`and acetyl, with particular preference being given to benzyl
`additional base, for example an alkali metal or alkaline-earth
`and acetyl.
`metal hydroxide or carbonate, such as sodium hydroxide,
`The functional derivatives of the compounds of the for-
`potassium hydroxide or calcium hydroxide, sodium carbon-
`mula I, which derivatives are to be used as starting com-
`ate, potassium carbonate or calcium carbonate, in an inert
`pounds, can be prepared by conventional methods as
`solvent, for example a halogenatcd hydrocarbon such as
`described, for example, in the standard works and Patent
`dichloromethane, an ether such as THF or dioxane, an amide
`Applications mentioned, for example by reaction of com- 15 such as DMF or dimethylacetamide, or a nitrile such as
`pounds which correspond to the formulae II and III but in
`acetonitrile, at temperatures of between about -10° and
`which at least one of these compounds contains a protective
`200°, preferably between 0° and 120°. The addition of an
`group instead of a hydrogen atom.
`iodide such as potassium iodide may favor the progress of
`The liberation of the compounds of the formula I from
`the reaction.
`their functional derivatives is achieved—depending on the 20
`The starting compounds of the formula II are in general
`protective group used—by employing, for example, strong
`known or can be prepared in an analogy to known com­
`acids, advantageously using trifluoroacetic or perchloric
`pounds. Their preparation is described, for example, in DE
`acid, but also with other strong inorganic acids such as
`37 23 797 (EP 300 272). They can be prepared, for example,
`hydrochloric acid or sulfuric acid, strong organic carboxylic
`by reacting an appropriately substituted aniline with allyl
`acids such as trichloroacetic acid or sulfonic acids such as 25 chloride, subsequently converting the double bond into a
`benzene- or p-toluenesulfonic acid. The presence of an
`diol, reacting this diol with a reactive derivative of carbonic
`additional inert solvent is possible, but not always necessary.
`acid, for example phosgene, N-N-carbonyldiimidazole, a
`Suitable inert solvents are preferably organic, for example
`dialkyl carbonate or diphosgene, oxidizing the product to
`carboxylic, acids such as acetic acid, ethers such as tetrahy-
`5-oxazolidinonecarboxylic acid and, if desired, carrying out
`drofuran (THF) or dioxane, amides such as dimethylforma- 30 further activation by derivatizing the acid group,
`mide (DMF), halogenated hydrocarbons such as dichlo­
`In a compound of the formula II it is possible to convert
`romethane, and also alcohols such as methanol, ethanol or
`a radical L into a different radical L by, for example, reacting
`isopropanol, and water. Also suitable are mixtures of the
`an OH group (Y=OH) with SOCl2, SOBr2, methanesulfo-
`abovementioned solvents. Trifluoroacetic acid is preferably
`nylchloride or p-toluenesulfonyl chloride.
`used in excess without the addition of a further solvent, 35
`The compounds of the formula III are, in general, known
`perchloric acid in the form of mixture of acetic acid and 70%
`and commercially available
`perchloric acid in a ratio of 9:1. The reaction temperatures
`The reaction of the oxazolidinones of the formula II with
`for the cleavage are advantageously between about 0° and
`the compounds of the formula III is carried out in a manner
`about 50°; it is preferably carried out at between 15° and 30°
`known per se, preferably in a protic or aprotic polar inert
`(room temperature).
`40 solvent at temperatures of between 20° and the boiling point
`The BOC group may, for example, preferably be elimi­
`of the solvent. The reaction times are from 10 min to 24 h,
`nated using 40% trifluoroacetic acid in dichloromethane or
`preferably from 2 h to 10 h.
`with from about 3 to 5N HC1 in dioxane at 15°-60°, and the
`Suitable solvents include, in particular, alcohols such as
`FMOC group removed using an approximately 5-20% solu-
`methanol, ethanol, isopropanol, n-butanol and tert-butanol;
`tion of dimethylamine, diethylamine or piperidine in DMF 45 ethers such as diethyl ether, diisopropyl ether, tetrahydro-
`at 15°-50o. Elimination of the DNP group is also achieved,
`fiiran (THF) and dioxane; glycol ethers such as ethylene
`for example, with an approximately 3-10% solution of
`glycol monomethyl and monoethyl ether (methyl glycol or
`2-mercaptoethanol in DMF/water at 15°-30°.
`ethyl glycol), and ethylene glycol dimethyl ether (diglyme);
`Protective groups which can be removed by hydrogenoly-
`ketones such as acetone and butanone; nitriles such as
`sis (e.g., BOM, CBZ or benzyl) may, for example, be 50 acetonitrile; nitro compounds such as nitromethane and
`eliminated by treatment with hydrogen in the presence of a
`nitrobenzene; esters such as ethyl acetate and hexameth-
`catalyst (e.g., a noble metal catalyst such as palladium,
`ylphosphoric triamide; sulfoxides such as dimethyl sulfox-
`advantageously on a support such as charcoal). In this case
`ide (DMSO); chlorinated hydrocarbons such as dichlo-
`suitable solvents are those indicated above, particular
`romethane,
`chloroform,
`trichloroethylene,
`1,2-
`examples being alcohols such as methanol or ethanol, or 55 dichloroethane and carbon tetrachloride; and hydrocarbons
`amides such as DMF. The hydrogenolysis is generally
`such as benzene, toluene and xylene. Also suitable are
`carried out at temperatures of between 0° and 100° and at
`mixtures of these solvents with one another. N-methylpyr-
`pressures of between 1 and 200 bar, preferably 20°-30o and
`rolidone is particularly suitable.
`1-10 bar. Hydrogenolysis of the CBZ group is readily
`Derivatives having a free primary or secondary amino
`achieved, for example, over 5-10% Pd-C in methanol at 60 group are advantageously converted into a protected form.
`20°-30°.
`Suitable protective groups are those mentioned above.
`It is also possible, for example, to perform a hydro-
`It is also possible to obtain a compound of the formula I
`genolytic conversion of a l,2,4-oxadiazolin-5-on-3-yl or a
`by converting a radical X into a different radical X. For
`5-alkyl-l,2,4-oxadiazol-3-yl group into amidine group by
`example, a free acid group (X=OH) can be esterified
`catalytic hydrogenation.
`65 (X=OA) or linked by a peptide bond to an amino acid or a
`Compounds of the formula I can also be obtained, pref­
`dipeptide. Furthermore, it is also possible, for example, to
`erably, by reaction of an oxazolidinone of the formula II
`convert an acid into an amide.
`
`

`
`5,614,535
`
`10
`9
`In addition, it is possible to obtain a compound of the
`indicated to be present, provided it is inert in this reaction.
`formula I by converting a radical R1 in a compound of the
`Furthermore, the addition of a base is advisable, especially
`formula I into a different radical R1.
`an alkali metal alcoholate such as potassium tert-butylate.
`In particular, cyano groups can be reduced to aminom-
`The reaction is advantageously carried out at a temperature
`of between 0° and 150°, preferably between 70° and 120°.
`ethyl groups or converted into amidino groups, benzyl 5
`The starting compounds of the formula IV are, in general,
`groups can be removed by hydrogenolysis, aminomethyl
`groups can be converted into guanidinomethyl groups, or
`novel. They are obtainable, for example, by reacting a
`ring-substituted aniline with an a-hydroxy-P-halocarboxylic
`nitrile groups can be converted into thiocarbamoyl groups.
`A reduction of cyano groups to aminomethyl groups is
`acid.
`carried out advantageously by catalytic hydrogenation, for 10
`It is possible, moreover, to obtain a compound of the
`example over Raney-Nickel at temperatures between 0° and
`formula I by reacting a diol of the formula V with an excess
`100°, preferably 10° and 30°, and at pressures between 1 and
`of a reactive carbonic acid derivative, a reaction which is
`200 bar, preferably at atmospheric pressure, in an inert
`preferably carried out under the abovementioned conditions.
`solvent, for example a lower alcohol such as methanol or
`While the carbonic acid derivatives are commercially avail-
`ethanol, advantageously in the presence of ammonia. If the 15 able, the compounds of the formula V can be obtained, for
`operation is carried out, for example, at about 20° and 1 bar,
`example, by reacting allyl chloride with p-aminobenzoni-
`then benzyl ester groups or N-benzyl groups present in the
`trile, converting the double bond into a dihydroxy grouping,
`starting material are retained. If it is desired to cleave these
`and reacting the resulting compound with hydroxylamine.
`by hydrogenolysis, then use is advantageously made of a
`A base of the formula I can be converted with an acid into
`noble metal catalyst, preferably Pd/charcoal, in which case 20
`the corresponding acid addition salt. Acids suitable for this
`it is possible to add to the solution an acid such as acetic
`reaction are in particular those which give physiologically
`acid, and also water.
`unobjectionable salts. For instance, it is possible to use
`In order to prepare compounds of the formula I in which
`inorganic acids, for example sulfuric acid, nitric acid, hydro-
`R1 is a guanidinophenyl group, a corresponding aminophe-
`halic acids such as hydrochloric acid or hydrobromic acid,
`nyl compound can be treated with an amidinating agent. A 25 phosphoric acids such as orthophosphoric acid, sulfamic
`preferred amidinating agent is l-amidino-3,5-dimethylpyra-
`acid, and also organic acids, especially aliphatic, alicyclic,
`zole, which is employed in particular in the form of its
`araliphatic, aromatic or heterocyclic mono- or polybasic
`nitrate. The operation is advantageously carried out with the
`carboxylic, sulfonic or sulfuric acids, for example formic
`addition of a base, such as triethylamine or ethyldiisopro-
`acid, acetic acid, trifluoroacetic acid, propionic acid, pivalic
`pylamine, in an inert solvent or solvent mixture, for example 30 acid, diethylacetic acid, malonic acid, succinic acid, pimelic
`water/dioxane, at temperatures of between 0° and 120°,
`acid, fumaric acid, maleic acid, lactic acid, tartaric acid.
`preferably between 60° and 120°.
`malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic
`In order to prepare an amidine of the formula I, ammonia
`acid, isonicotinic acid, methane- or ethanesulfonic acid,
`ethanedisulfonic acid, 2-hydroxyethanesulfomc acid, benze-
`can be added on to a nitrile of the formula I. The addition is
`preferably accomplished over two or more stages in a 35 nesulfonic acid, p-toluenesulfonic acid, naphthalenemono-
`and -disulfonic acids, and lauryl sulfuric acid.
`manner known per se by a) converting the nitrile with H2S
`The free bases of the formula I may, if desired, be
`into a thioamide which is converted with an alkylating agent,
`for example CH3I, into the corresponding S-alkyl-imidothio
`liberated from their salts by treatment with strong bases such
`as sodium hydroxide or potassium hydroxide, sodium car-
`ester, which in turn is reacted with NH3 to give the amidine,
`b) converting the nitrile with an alcohol, for example etha- 40 bonate or potassium carbonate,
`nol, in the presence of HC1 into the corresponding imido
`It is also possible to convert carboxylic acids of the
`formula I, by reaction with corresponding bases, into their
`ester and treating the latter with ,ammonia, or c) reacting the
`nitrile with lithium bis(trimethylsilyl)amide and then hydro-
`metal or ammonium salts, for example their sodium, potas­
`lyzing the product.
`sium or calcium salts.
`Analogously, the corresponding N-hydroxy amidines of 45
`The compounds of the formula I may contain one or more
`the formula I are obtainable from the nitriles by working in
`chiral centers and may therefore be present in racemic or in
`accordance with a) or b) but using hydroxylamine instead of
`optically active form. Racemates which are obtained can be
`ammonia.
`separated by methods which are known per se, mechanically
`Furthermore, N-hydroxyamidines can be converted, by
`or chemically, into the enantiomers.
`Preferably, diastereomers are formed from the racemic
`reaction with aliphatic carbonyl chlorides, into 1,2,4-oxa- 50
`mixture by reaction with an optically active resolving agent.
`diazoles or 1,2,4-oxadiazolinones, which can then be con­
`Examples of suitable resolving agents are optically active
`verted, by catalytic hydrogenation over, for example, Raney-
`acids, such as the D and L forms of tartaric acid, diacetyl-
`Ni, Pd/C or Pt02, preferably in MeOH, dioxane, glacial
`tartaric acid, dibenzoyltartaric acid, mandelic acid, malic
`acetic acid, glacial acetic acid/acetic anhydride or DMF, into
`55 acid, lactic acid or the various optically active camphorsul-
`amidines.
`fonic acids such as (3-camphorsulfonic acid.
`Furthermore, a compound of the formula I can be
`Also advantageous is an enantiomeric resolution using a
`obtained by reacting a compound of the formula IV with a
`column packed with an optically active resolving agent (e.g.,
`reactive derivative of carbonic acid. Reactive derivatives of
`dinitrobenzoylphenylglycine); a suitable eluent is, for
`carbonic acid may, for example, be those mentioned above,
`with particular preference being given to phosgene and 60 example, a hexane/isopropanol/acetonitrile mixture,
`It is of course also possible to obtain optically active
`diphosgene and to N,N-carbonyldiimidazole. Further suit­
`compounds of the formula I in accordance with the methods
`able carbonic acid derivatives are, in particular, dialkyl
`described above by using starting compounds (e.g., those of

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket